Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 700 of 2873 entries
View as:

Effects of Cancer Symptoms on Caregivers

Phase: N/A Priority: Normal
NCT ID: NCT00351988 Org: User:
Start: 01/26/06 End: 01/20/22 Due: 01/20/23

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Phase: N/A Priority: Normal
NCT ID: NCT06162377 Org: User:
Start: 01/10/24 End: 12/31/25 Due: 12/31/26

Developing an eLearning Program in Helping Spanish and Portuguese Speaking Cancer Care Providers During Tobacco Use Counselling

Phase: N/A Priority: Normal
NCT ID: NCT03539991 Org: User:
Start: 04/18/18 End: 08/17/21 Due: 08/17/22

Gene Polymorphisms and Symptoms in Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00504374 Org: User:
Start: 06/13/06 End: 04/27/17 Due: 04/27/18

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01067066 Org: User:
Start: 02/03/10 End: 07/06/16 Due: 07/06/17

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase: N/A Priority: Normal
NCT ID: NCT02456857 Org: User:
Start: 01/12/16 End: 05/24/23 Due: 05/24/24

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00411632 Org: User:
Start: 11/29/06 End: 02/23/18 Due: 02/23/19

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Phase: N/A Priority: Normal
NCT ID: NCT00829959 Org: User:
Start: 02/28/09 End: 08/31/16 Due: 08/31/17

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Phase: N/A Priority: Normal
NCT ID: NCT00478686 Org: User:
Start: 05/23/07 End: 05/02/17 Due: 05/02/18

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Phase: N/A Priority: Normal
NCT ID: NCT01730586 Org: User:
Start: 11/30/12 End: 08/31/16 Due: 08/31/17

Rational Therapeutics Based on Matched Tumor and Normal Tissue

Phase: N/A Priority: Normal
NCT ID: NCT02272595 Org: User:
Start: 11/04/14 End: 01/11/22 Due: 01/11/23

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT00006079 Org: User:
Start: 06/19/98 End: 04/27/04 Due: 04/27/05

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00080808 Org: User:
Start: 08/31/01 End: 07/31/09 Due: 07/31/10

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT01751425 Org: User:
Start: 07/24/13 End: 09/24/19 Due: 09/24/20

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05055063 Org: User:
Start: 05/18/22 End: 02/02/27 Due: 02/02/28

Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003599 Org: User:
Start: - End: - Due: -

Papillary Serous Carcinoma of the Endometrium

Phase: N/A Priority: Normal
NCT ID: NCT00515073 Org: User:
Start: 04/30/01 End: 05/31/13 Due: 05/31/14

Locus of Control and Spirituality in Palliative Care Patients

Phase: N/A Priority: Normal
NCT ID: NCT00477243 Org: User:
Start: 06/03/04 End: 08/11/17 Due: 08/11/18

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Phase: N/A Priority: Normal
NCT ID: NCT05092451 Org: User:
Start: 11/01/22 End: 08/31/26 Due: 08/31/27

PP-Gemcitabine & External Beam Radiation-Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT02046304 Org: User:
Start: 12/31/01 End: 03/31/15 Due: 03/31/16

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Phase: N/A Priority: Normal
NCT ID: NCT05285813 Org: User:
Start: 05/06/22 End: 12/31/26 Due: 12/31/27

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04774393 Org: User:
Start: 05/24/21 End: 11/29/25 Due: 11/29/26

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00634894 Org: User:
Start: 03/31/08 End: 09/30/08 Due: 09/30/09

Exemestane-RAD001-Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01627067 Org: User:
Start: 09/30/12 End: 02/01/19 Due: 02/01/20

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase: N/A Priority: Normal
NCT ID: NCT01430572 Org: User:
Start: 10/07/11 End: 05/12/20 Due: 05/12/21